# Vivos Therapeutics, Inc.: overview VVOS · Nasdaq · CIK 1716166 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/vvos.md) · [Financials](/companies/vvos/financials.md) · [Filings](/companies/vvos/filings.md) · [Insiders](/companies/vvos/insiders.md) Latest reported revenue: [$5.2m](/filings/0001493152-26-038336.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-038336). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [3,860](/filings/0001493152-25-024253.md) | [3,698 d](/filings/0001493152-26-016854.md) | [3,016](/filings/0001493152-26-024650.md) | [3,820](/filings/0001493152-26-038336.md) | [6,783](/filings/0001493152-25-024253.md) | [3,824 d](/filings/0001493152-26-016854.md) | [5,141](/filings/0001493152-26-024650.md) | [5,153](/filings/0001493152-26-038336.md) | | Gross margin | % | [60.5%](/filings/0001493152-25-024253.md) | [56.7% d](/filings/0001493152-26-016854.md) | [50.0%](/filings/0001493152-26-024650.md) | [55.2%](/filings/0001493152-26-038336.md) | [58.0%](/filings/0001493152-25-024253.md) | [78.1% d](/filings/0001493152-26-016854.md) | [59.5%](/filings/0001493152-26-024650.md) | [57.3%](/filings/0001493152-26-038336.md) | | Operating margin | % | [(68.5%)](/filings/0001493152-25-024253.md) | [(75.9%) d](/filings/0001493152-26-016854.md) | [(129.9%)](/filings/0001493152-26-024650.md) | [(127.4%)](/filings/0001493152-26-038336.md) | [(69.8%)](/filings/0001493152-25-024253.md) | [(166.9%) d](/filings/0001493152-26-016854.md) | [(128.7%)](/filings/0001493152-26-024650.md) | [(93.6%)](/filings/0001493152-26-038336.md) | | Net margin | % | [(67.8%)](/filings/0001493152-25-024253.md) | [(76.4%) d](/filings/0001493152-26-016854.md) | [(128.1%)](/filings/0001493152-26-024650.md) | [(131.2%)](/filings/0001493152-26-038336.md) | [(79.6%)](/filings/0001493152-25-024253.md) | [(180.3%) d](/filings/0001493152-26-016854.md) | [(149.4%)](/filings/0001493152-26-024650.md) | [(106.4%)](/filings/0001493152-26-038336.md) | | Diluted EPS | $ per share | [(0.40)](/filings/0001493152-25-024253.md) | not reported | [(0.45)](/filings/0001493152-26-024650.md) | [(0.55)](/filings/0001493152-26-038336.md) | [(0.49)](/filings/0001493152-25-024253.md) | not reported | [(0.52)](/filings/0001493152-26-024650.md) | [(0.31)](/filings/0001493152-26-038336.md) | | Free cash flow | $k | [(4,379) d](/filings/0001493152-25-024253.md) | [(3,105) d](/filings/0001493152-26-016854.md) | [(3,918)](/filings/0001493152-26-024650.md) | [(4,265) d](/filings/0001493152-26-038336.md) | [(4,244) d](/filings/0001493152-25-024253.md) | [(5,343) d](/filings/0001493152-26-016854.md) | [(6,028)](/filings/0001493152-26-024650.md) | [(3,564) d](/filings/0001493152-26-038336.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [16.9](/filings/0001493152-23-009765.md) | [16.0](/filings/0001493152-24-029491.md) | [13.8](/filings/0001641172-25-001750.md) | [15.0](/filings/0001493152-26-016854.md) | [17.4](/filings/0001493152-26-016854.md) | | Gross margin | % | [74.6%](/filings/0001493152-23-009765.md) | [62.5%](/filings/0001493152-24-029491.md) | [59.9%](/filings/0001641172-25-001750.md) | [60.0%](/filings/0001493152-26-016854.md) | [60.4%](/filings/0001493152-26-016854.md) | | Operating margin | % | [(120.7%)](/filings/0001493152-23-009765.md) | [(156.2%)](/filings/0001493152-24-029491.md) | [(125.3%)](/filings/0001641172-25-001750.md) | [(74.3%)](/filings/0001493152-26-016854.md) | [(114.1%)](/filings/0001493152-26-016854.md) | | Net margin | % | [(120.2%)](/filings/0001493152-23-009765.md) | [(148.8%)](/filings/0001493152-24-029491.md) | [(98.4%)](/filings/0001641172-25-001750.md) | [(74.1%)](/filings/0001493152-26-016854.md) | [(121.4%)](/filings/0001493152-26-016854.md) | | Diluted EPS | $ per share | [(0.96)](/filings/0001493152-22-008452.md) | [(25.90)](/filings/0001493152-24-029491.md) | [(11.14)](/filings/0001641172-25-001750.md) | [(2.22)](/filings/0001493152-26-016854.md) | [(2.07)](/filings/0001493152-26-016854.md) | | Free cash flow | $m | [(18.1)](/filings/0001493152-23-009765.md) | [(20.5)](/filings/0001493152-24-029491.md) | [(12.7)](/filings/0001641172-25-001750.md) | [(13.3)](/filings/0001493152-26-016854.md) | [(17.6)](/filings/0001493152-26-016854.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/vvos/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $38.6k | 85,001 | | Reduced −10,542 | | [IHT Wealth Management, LLC](/funds/1697490.md) | 2026-06-30 | $34.9k | 76,736 | | Added +35,675 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $27.6k | 60,629 | | Reduced −212,700 | | [COMMONWEALTH EQUITY SERVICES, LLC](/funds/312272.md) | 2026-06-30 | $19.3k | 42,500 | | Unchanged | | [B. Riley Wealth Advisors, Inc.](/funds/1464811.md) | 2026-06-30 | $18.8k | 38,066 | | Unchanged | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $17.8k | 39,154 | | Added +28,108 | | [Centurion Wealth Management LLC](/funds/1951368.md) | 2026-06-30 | $16.2k | 35,684 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $12.6k | 27,817 | | Unchanged | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $11.3k | 24,922 | | Unchanged | | [Sequoia Financial Advisors, LLC](/funds/1599900.md) | 2026-06-30 | $10.9k | 24,000 | | Unchanged | ## Recent filings [All 299 filings](/companies/vvos/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-21 | 07:00 ET | [8-K](/filings/0001493152-26-047841.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-047841 | | 2026-10-19 | 16:49 ET | [8-K](/filings/0001493152-26-047601.md) | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-047601 | | 2026-10-15 | 08:45 ET | [8-K](/filings/0001493152-26-047158.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-047158 | | 2026-10-01 | 21:54 ET | [8-K](/filings/0001493152-26-045193.md) | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001493152-26-045193 | | 2026-09-08 | 17:29 ET | [8-K/A](/filings/0001493152-26-041807.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-26-041807 | | 2026-09-08 | 18:26 ET | [8-K](/filings/0001493152-26-041616.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-26-041616 | | 2026-08-21 | 17:30 ET | [8-K](/filings/0001493152-26-039736.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-039736 | | 2026-08-14 | 16:07 ET | [10-Q](/filings/0001493152-26-038336.md) | Quarterly report, period 2026-06-30 | 0001493152-26-038336 | | 2026-08-11 | 17:02 ET | [8-K](/filings/0001493152-26-037173.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-037173 | | 2026-08-03 | 17:29 ET | [8-K](/filings/0001493152-26-035867.md) | 1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-035867 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-016854.md), filed Apr 15, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/e86ec83f-6a83-4169-b7bc-f10f50702032) ## About the filer - CIK: 1716166 - Tickers: VVOS - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 15:56 ET. No prices; not investment advice.